UNITED STATES DEPARTMENT OF THE
TREASURY
1500 PENNSYLVANIA AVENUE,
NW
WASHINGTON, D.C. 20220
Dear Ladies and
Gentlemen:
The company set forth on the signature page
hereto (the “ Company ”) intends to issue in a
private placement the number of shares of a series of its preferred
stock set forth on Schedule A hereto (the “ Preferred
Shares ”) and a warrant to purchase the number of shares
of its common stock set forth on Schedule A hereto (the “
Warrant ” and, together with the Preferred Shares, the
“ Purchased Securities ”) and the United States
Department of the Treasury (the “ Investor ”)
intends to purchase from the Company the Purchased
Securities.
The purpose of this letter agreement is to
confirm the terms and conditions of the purchase by the Investor of
the Purchased Securities. Except to the extent supplemented or
superseded by the terms set forth herein or in the Schedules
hereto, the provisions contained in the Securities Purchase
Agreement – Standard Terms attached hereto as Exhibit A (the
“ Securities Purchase Agreement ”) are
incorporated by reference herein. Terms that are defined in the
Securities Purchase Agreement are used in this letter agreement as
so defined. In the event of any inconsistency between this letter
agreement and the Securities Purchase Agreement, the terms of this
letter agreement shall govern.
Each of the Company and the Investor hereby
confirms its agreement with the other party with respect to the
issuance by the Company of the Purchased Securities and the
purchase by the Investor of the Purchased Securities pursuant to
this letter agreement and the Securities Purchase Agreement on the
terms specified on Schedule A hereto.
This letter agreement (including the Schedules
hereto) and the Securities Purchase Agreement (including the
Annexes thereto) and the Warrant constitute the entire agreement,
and supersede all other prior agreements, understandings,
representations and warranties, both written and oral, between the
parties, with respect to the subject matter hereof. This letter
agreement constitutes the “Letter Agreement” referred
to in the Securities Purchase Agreement.
This letter agreement may be executed in any
number of separate counterparts, each such counterpart being deemed
to be an original instrument, and all such counterparts will
together constitute the same agreement. Executed signature pages to
this letter agreement may be delivered by facsimile and such
facsimiles will be deemed as sufficient as if actual signature
pages had been delivered.
***
In witness whereof, this letter agreement has
been duly executed and delivered by the duly authorized
representatives of the parties hereto as of the date written
below.
UNITED STATES DEPARTMENT OF THE TREASURY
Title: Interim Assistant
Secretary
COMPANY: PEOPLES BANCORP INC.
Title: President and Chief
Executive Officer
SECURITIES PURCHASE
AGREEMENT
|
SECURITIES PURCHASE
AGREEMENT
STANDARD TERMS
|
TABLE OF CONTENTS
Page
Article I
Purchase; Closing
Article II
Representations and
Warranties
|
|
Representations
and Warranties of the Company
|
5
|
Article III
Covenants
|
|
Commercially
Reasonable Efforts
|
13
|
|
|
Sufficiency of
Authorized Common Stock; Exchange Listing
|
14
|
|
|
Certain
Notifications Until Closing
|
15
|
|
|
Access,
Information and Confidentiality
|
16
|
Article IV
Additional Agreements
|
|
Purchase for
Investment
|
16
|
|
|
Transfer of
Purchased Securities and Warrant Shares; Restrictions on Exercise
of the Warrant
|
18
|
|
|
Voting of
Warrant Shares
|
30
|
|
|
Restriction on
Dividends and Repurchases
|
31
|
|
|
Repurchase of
Investor Securities
|
32
|
|
|
Executive
Compensation
|
33
|
|
|
Bank and Thrift
Holding Company Status
|
33
|
|
|
Predominantly
Financial
|
34
|
Article V
Miscellaneous
|
|
Survival of
Representations and Warranties
|
35
|
|
|
Governing
Law: Submission to Jurisdiction, Etc.
|
35
|
|
|
No Third Party
Beneficiaries
|
37
|
LIST OF ANNEXES
ANNEX
A: FORM
OF CERTIFICATE OF DESIGNATIONS FOR PREFERRED STOCK
ANNEX
B: FORM
OF WAIVER
ANNEX
C: FORM
OF OPINION
ANNEX
D: FORM
OF WARRANT
INDEX OF
DEFINED TERMS
|
|
|
Location of
Definition
|
|
Affiliate
|
|
5.7(b)
|
|
Agreement
|
|
Recitals
|
|
Appraisal
Procedure
|
|
4.9(c)(i)
|
|
Appropriate
Federal Banking Agency
|
|
2.2(s)
|
|
Bank Holding
Company
|
|
4.11
|
|
Bankruptcy
Exceptions
|
|
2.2(d)
|
|
Benefit
Plans
|
|
1.2(d)(iv)
|
|
Board of
Directors
|
|
2.2(f)
|
|
Business
Combination
|
|
4.4
|
|
business
day
|
|
1.3
|
|
Capitalization
Date
|
|
2.2(b)
|
|
Certificate of
Designations
|
|
1.2(d)
(iii)
|
|
Charter
|
|
1.2(d)(iii)
|
|
Closing
|
|
1.2(a)
|
|
Closing
Date
|
|
1.2(a)
|
|
Code
|
|
2.2(n)
|
|
Common
Stock
|
|
Recitals
|
|
Company
|
|
Recitals
|
|
Company
Financial Statements
|
|
2.2(h)
|
|
Company
Material Adverse Effect
|
|
2.1(a)
|
|
Company
Reports
|
|
2.2(i)(i)
|
|
Company
Subsidiary; Company Subsidiaries
|
|
2.2(i)(i)
|
|
control;
controlled by; under common control with
|
|
5.7(b)
|
|
Controlled
Group
|
|
2.2(n)
|
|
CPP
|
|
Recitals
|
|
EESA
|
|
1.2(d)(iv)
|
|
ERISA
|
|
2.2(n)
|
|
Exchange
Act
|
|
2.1(b)
|
|
Fair Market
Value
|
|
4.9(c)(ii)
|
|
Federal
Reserve
|
|
4.11
|
|
GAAP
|
|
2.1(a)
|
|
Governmental
Entities
|
|
1.2(c)
|
|
Holder
|
|
4.5(k)(i)
|
|
Holders’
Counsel
|
|
4.5(k)(ii)
|
|
Indemnitee
|
|
4.5(g)(i)
|
|
Information
|
|
3.5(b)
|
|
Initial Warrant
Shares
|
|
Recitals
|
|
Investor
|
|
Recitals
|
|
Junior
Stock
|
|
4.8(c)
|
|
knowledge of
the Company; Company’s knowledge
|
|
5.7(c)
|
|
Last Fiscal
Year
|
|
2.1(b)
|
|
Term
|
|
Location
of Definition
|
|
Letter
Agreement
|
|
Recitals
|
|
officers
|
|
5.7(c)
|
|
Parity
Stock
|
|
4.8(c)
|
|
Pending
Underwritten Offering
|
|
4.5(l)
|
|
Permitted
Repurchases
|
|
4.8(a)(ii)
|
|
Piggyback
Registration
|
|
4.5(a)(iv)
|
|
Plan
|
|
2.2(n)
|
|
Preferred
Shares
|
|
Recitals
|
|
Preferred
Stock
|
|
Recitals
|
|
Previously
Disclosed
|
|
2.1(b)
|
|
Proprietary
Rights
|
|
2.2(u)
|
|
Purchase
|
|
Recitals
|
|
Purchase
Price
|
|
1.1
|
|
Purchased
Securities
|
|
Recitals
|
|
Qualified
Equity Offering
|
|
4.4
|
|
register;
registered; registration
|
|
4.5(k)(iii)
|
|
Registrable
Securities
|
|
4.5(k)(iv)
|
|
Registration
Expenses
|
|
4.5(k)(v)
|
|
Regulatory
Agreement
|
|
2.2(s)
|
|
Rule 144; Rule
144A; Rule 159A; Rule 405; Rule 415
|
|
4.5(k)(vi)
|
|
Savings and
Loan Holding Company
|
|
4.11
|
|
Schedules
|
|
Recitals
|
|
SEC
|
|
2.1(b)
|
|
Securities
Act
|
|
2.2(a)
|
|
Selling
Expenses
|
|
4.5(k)(vii)
|
|
Senior
Executive Officers
|
|
4.10
|
|
Share Dilution
Amount
|
|
4.8(a)(ii)
|
|
Shelf
Registration Statement
|
|
4.5(a)(ii)
|
|
Signing
Date
|
|
2.1(a)
|
|
Special
Registration
|
|
4.5(i)
|
|
Stockholder
Proposals
|
|
3.1(b)
|
|
subsidiary
|
|
5.8(a)
|
|
Tax;
Taxes
|
|
2.2(o)
|
|
Transfer
|
|
4.4
|
|
Warrant
|
|
Recitals
|
|
Warrant
Shares
|
|
2.2(d)
|
SECURITIES PURCHASE AGREEMENT
– STANDARD TERMS
Recitals:
WHEREAS, the United States Department of the
Treasury (the “ Investor ”) may from time to
time agree to purchase shares of preferred stock and warrants from
eligible financial institutions which elect to participate in the
Troubled Asset Relief Program Capital Purchase Program (“
CPP ”);
WHEREAS, an eligible financial institution
electing to participate in the CPP and issue securities to the
Investor (referred to herein as the “ Company ”)
shall enter into a letter agreement (the “ Letter
Agreement ”) with the Investor which incorporates this
Securities Purchase Agreement – Standard Terms;
WHEREAS, the Company agrees to expand the flow
of credit to U.S. consumers and businesses on competitive terms to
promote the sustained growth and vitality of the U.S.
economy;
WHEREAS, the Company agrees to work diligently,
under existing programs, to modify the terms of residential
mortgages as appropriate to strengthen the health of the U.S.
housing market;
WHEREAS, the Company intends to issue in a
private placement the number of shares of the series of its
Preferred Stock (“ Preferred Stock ”) set forth
on Schedule A to the Letter Agreement (the “
Preferred Shares ”) and a warrant to purchase the
number of shares of its Common Stock (“ Common Stock
”) set forth on Schedule A to the Letter Agreement
(the “ Initial Warrant Shares ”) (the “
Warrant ” and, together with the Preferred Shares, the
“ Purchased Securities ”) and the Investor
intends to purchase (the “ Purchase ”) from the
Company the Purchased Securities; and
WHEREAS, the Purchase will be governed by this
Securities Purchase Agreement – Standard Terms and the Letter
Agreement, including the schedules thereto (the “
Schedules ”), specifying additional terms of the
Purchase. This Securities Purchase Agreement –
Standard Terms (including the Annexes hereto) and the Letter
Agreement (including the Schedules thereto) are together referred
to as this “Agreement”. All references in
this Securities Purchase Agreement – Standard Terms to
“Schedules” are to the Schedules attached to the Letter
Agreement.
NOW, THEREFORE , in consideration of the premises, and of the
representations, warranties, covenants and agreements set forth
herein, the parties agree as follows:
Article I
Purchase; Closing
1.1
Purchase . On the terms and subject to the
conditions set forth in this Agreement, the Company agrees to sell
to the Investor, and the Investor agrees to purchase from the
Company, at the Closing (as hereinafter defined), the Purchased
Securities for the price set forth on Schedule A (the
“ Purchase Price ”).
1.2
Closing .
(a) On
the terms and subject to the conditions set forth in this
Agreement, the closing of the Purchase (the “ Closing
”) will take place at the location specified in Schedule
A , at the time and on the date set forth in Schedule A
or as soon as practicable thereafter, or at such other place, time
and date as shall be agreed between the Company and the
Investor. The time and date on which the Closing occurs
is referred to in this Agreement as the “ Closing Date
”.
(b) Subject
to the fulfillment or waiver of the conditions to the Closing in
this Section 1.2, at the Closing the Company will deliver the
Preferred Shares and the Warrant, in each case as evidenced by one
or more certificates dated the Closing Date and bearing appropriate
legends as hereinafter provided for, in exchange for payment in
full of the Purchase Price by wire transfer of immediately
available United States funds to a bank account designated by the
Company on Schedule A .
(c) The
respective obligations of each of the Investor and the Company to
consummate the Purchase are subject to the fulfillment (or waiver
by the Investor and the Company, as applicable) prior to the
Closing of the conditions that (i) any approvals or authorizations
of all United States and other governmental, regulatory or judicial
authorities (collectively, “ Governmental Entities
”) required for the consummation of the Purchase shall have
been obtained or made in form and substance reasonably satisfactory
to each party and shall be in full force and effect and all waiting
periods required by United States and other applicable law, if any,
shall have expired and (ii) no provision of any applicable United
States or other law and no judgment, injunction, order or decree of
any Governmental Entity shall prohibit the purchase and sale of the
Purchased Securities as contemplated by this Agreement.
(d) The
obligation of the Investor to consummate the Purchase is also
subject to the fulfillment (or waiver by the Investor) at or prior
to the Closing of each of the following conditions:
(i) (A)
the representations and warranties of the Company set forth in (x)
Section 2.2(g) of this Agreement shall be true and correct in all
respects as though made on and as of the Closing Date, (y) Sections
2.2(a) through (f) shall be true and correct in all material
respects as though made on and as of the Closing Date (other than
representations and warranties that by their terms speak as of
another date, which representations and warranties shall be true
and correct in all material respects as of such other date) and (z)
Sections 2.2(h) through (v) (disregarding all qualifications or
limitations set forth in such representations and warranties as to
“materiality”, “Company Material Adverse
Effect” and words of similar import) shall be true and
correct as though made on and as of the Closing Date (other than
representations and warranties that by their terms speak as of
another date, which representations and warranties shall be true
and correct as of such other date), except to the extent that the
failure of such representations and warranties referred to in this
Section 1.2(d)(i)(A)(z) to be so true and correct, individually or
in the aggregate, does not have and would not reasonably be
expected to have a Company Material Adverse Effect and (B) the
Company shall have performed in all material respects all
obligations required to be performed by it under this Agreement at
or prior to the Closing;
(ii) the
Investor shall have received a certificate signed on behalf of the
Company by a senior executive officer certifying to the effect that
the conditions set forth in Section 1.2(d)(i) have been
satisfied;
(iii) the
Company shall have duly adopted and filed with the Secretary of
State of its jurisdiction of organization or other applicable
Governmental Entity the amendment to its certificate or articles of
incorporation, articles of association, or similar organizational
document (“ Charter ”) in substantially the form
attached hereto as Annex A (the “ Certificate of
Designations ”) and such filing shall have been
accepted;
(iv) (A)
the Company shall have effected such changes to its compensation,
bonus, incentive and other benefit plans, arrangements and
agreements (including golden parachute, severance and employment
agreements) (collectively, “ Benefit Plans ”)
with respect to its Senior Executive Officers (and to the extent
necessary for such changes to be legally enforceable, each of its
Senior Executive Officers shall have duly consented in writing to
such changes), as may be necessary, during the period that the
Investor owns any debt or equity securities of the Company acquired
pursuant to this Agreement or the Warrant, in order to comply with
Section 111(b) of the Emergency Economic Stabilization Act of 2008
(“ EESA ”) as implemented by guidance or
regulation thereunder that has been issued and is in effect as of
the Closing Date, and (B) the Investor shall have received a
certificate signed on behalf of the Company by a senior executive
officer certifying to the effect that the condition set forth in
Section 1.2(d)(iv)(A) has been satisfied;
(v) each
of the Company’s Senior Executive Officers shall have
delivered to the Investor a written waiver in the form attached
hereto as Annex B releasing the Investor from any claims
that such Senior Executive Officers may otherwise have as a result
of the issuance, on or prior to the Closing Date, of any
regulations which require the modification of, and the agreement of
the Company hereunder to modify, the terms of any Benefit Plans
with respect to its Senior Executive Officers to eliminate any
provisions of such Benefit Plans that would not be in compliance
with the requirements of Section 111(b) of the EESA as implemented
by guidance or regulation thereunder that has been issued and is in
effect as of the Closing Date;
(vi) the
Company shall have delivered to the Investor a written opinion from
counsel to the Company (which may be internal counsel), addressed
to the Investor and dated as of the Closing Date, in substantially
the form attached hereto as Annex C ;
(vii) the
Company shall have delivered certificates in proper form or, with
the prior consent of the Investor, evidence of shares in book-entry
form, evidencing the Preferred Shares to Investor or its
designee(s); and
(viii) the
Company shall have duly executed the Warrant in substantially the
form attached hereto as Annex D and delivered such executed
Warrant to the Investor or its designee(s).
1.3
Interpretation . When a reference is made in this
Agreement to “Recitals,” “Articles,”
“Sections,” or “Annexes” such reference
shall be to a Recital, Article or Section of, or Annex to, this
Securities Purchase Agreement – Standard Terms, and a
reference to “Schedules” shall be to a Schedule to the
Letter Agreement, in each case, unless otherwise
indicated. The terms defined in the singular have a
comparable meaning when used in the plural, and vice
versa. References to “herein”,
“hereof”, “hereunder” and the like refer to
this Agreement as a whole and not to any particular section or
provision, unless the context requires otherwise. The
table of contents and headings contained in this Agreement are for
reference purposes only and are not part of this
Agreement. Whenever the words “include,”
“includes” or “including” are used in this
Agreement, they shall be deemed followed by the words
“without limitation.” No rule of construction against
the draftsperson shall be applied in connection with the
interpretation or enforcement of this Agreement, as this Agreement
is the product of negotiation between sophisticated parties advised
by counsel. All references to “$” or
“dollars” mean the lawful currency of the United States
of America. Except as expressly stated in this
Agreement, all references to any statute, rule or regulation are to
the statute, rule or regulation as amended, modified, supplemented
or replaced from time to time (and, in the case of statutes,
include any rules and regulations promulgated under the statute)
and to any section of any statute, rule or regulation include any
successor to the section. References to a “
business day ” shall mean any day except Saturday,
Sunday and any day on which banking institutions in the State of
New York generally are authorized or required by law or other
governmental actions to close.
Article II
Representations and
Warranties
2.1
Disclosure .
(a) “
Company Material Adverse Effect ” means a material
adverse effect on (i) the business, results of operation or
financial condition of the Company and its consolidated
subsidiaries taken as a whole; provided, however , that
Company Material Adverse Effect shall not be deemed to include the
effects of (A) changes after the date of the Letter Agreement (the
“ Signing Date ”) in general business, economic
or market conditions (including changes generally in prevailing
interest rates, credit availability and liquidity, currency
exchange rates and price levels or trading volumes in the United
States or foreign securities or credit markets), or any outbreak or
escalation of hostilities, declared or undeclared acts of war or
terrorism, in each case generally affecting the industries in which
the Company and its subsidiaries operate, (B) changes or proposed
changes after the Signing Date in generally accepted accounting
principles in the United States (“ GAAP ”) or
regulatory accounting requirements, or authoritative
interpretations thereof, (C) changes or proposed changes after the
Signing Date in securities, banking and other laws of general
applicability or related policies or interpretations of
Governmental Entities (in the case of each of these clauses (A),
(B) and (C), other than changes or occurrences to the extent that
such changes or occurrences have or would reasonably be expected to
have a materially disproportionate adverse effect on the Company
and its consolidated subsidiaries taken as a whole relative to
comparable U.S. banking or financial services organizations), or
(D) changes in the market price or trading volume of the Common
Stock or any other equity, equity-related or debt securities of the
Company or its consolidated subsidiaries (it being understood and
agreed that the exception set forth in this clause (D) does not
apply to the underlying reason giving rise to or contributing to
any such change); or (ii) the ability of the Company to consummate
the Purchase and the other transactions contemplated by this
Agreement and the Warrant and perform its obligations hereunder or
thereunder on a timely basis.
(b) “
Previously Disclosed ” means information set forth or
incorporated in the Company’s Annual Report on Form 10-K for
the most recently completed fiscal year of the Company filed with
the Securities and Exchange Commission (the “ SEC
”) prior to the Signing Date (the “ Last Fiscal
Year ”) or in its other reports and forms filed with or
furnished to the SEC under Sections 13(a), 14(a) or 15(d) of the
Securities Exchange Act of 1934 (the “ Exchange Act
”) on or after the last day of the Last Fiscal Year and prior
to the Signing Date.
2.2
Representations and Warranties of the Company
. Except as Previously Disclosed, the Company represents
and warrants to the Investor that as of the Signing Date and as of
the Closing Date (or such other date specified herein):
(a)
Organization, Authority and Significant Subsidiaries
. The Company has been duly incorporated and is validly
existing and in good standing under the laws of its jurisdiction of
organization, with the necessary power and authority to own its
properties and conduct its business in all material respects as
currently conducted, and except as has not, individually or in the
aggregate, had and would not reasonably be expected to have a
Company Material Adverse Effect, has been duly qualified as a
foreign corporation for the transaction of business and is in good
standing under the laws of each other jurisdiction in which it owns
or leases properties or conducts any business so as to require such
qualification; each subsidiary of the Company that is a
“significant subsidiary” within the meaning of Rule
1-02(w) of Regulation S-X under the Securities Act of 1933 (the
“ Securities Act ”) has been duly organized and
is validly existing in good standing under the laws of its
jurisdiction of organization. The Charter and bylaws of
the Company, copies of which have been provided to the Investor
prior to the Signing Date, are true, complete and correct copies of
such documents as in full force and effect as of the Signing
Date.
(b)
Capitalization . The authorized capital stock of
the Company, and the outstanding capital stock of the Company
(including securities convertible into, or exercisable or
exchangeable for, capital stock of the Company) as of the most
recent fiscal month-end preceding the Signing Date (the “
Capitalization Date ”) is set forth on Schedule
B . The outstanding shares of capital stock of the
Company have been duly authorized and are validly issued and
outstanding, fully paid and nonassessable, and subject to no
preemptive rights (and were not issued in violation of any
preemptive rights). Except as provided in the Warrant,
as of the Signing Date, the Company does not have outstanding any
securities or other obligations providing the holder the right to
acquire Common Stock that is not reserved for issuance as specified
on Schedule B , and the Company has not made any other
commitment to authorize, issue or sell any Common
Stock. Since the Capitalization Date, the Company has
not issued any shares of Common Stock, other than (i) shares issued
upon the exercise of stock options or delivered under other
equity-based awards or other convertible securities or warrants
which were issued and outstanding on the Capitalization Date and
disclosed on Schedule B and (ii) shares disclosed on
Schedule B .
(c)
Preferred Shares . The Preferred Shares have been
duly and validly authorized, and, when issued and delivered
pursuant to this Agreement, such Preferred Shares will be duly and
validly issued and fully paid and non-assessable, will not be
issued in violation of any preemptive rights, and will rank pari
passu with or senior to all other series or classes of
Preferred Stock, whether or not issued or outstanding, with respect
to the payment of dividends and the distribution of assets in the
event of any dissolution, liquidation or winding up of the
Company.
(d)
The Warrant and Warrant Shares . The Warrant has
been duly authorized and, when executed and delivered as
contemplated hereby, will constitute a valid and legally binding
obligation of the Company enforceable against the Company in
accordance with its terms, except as the same may be limited by
applicable bankruptcy, insolvency, reorganization, moratorium or
similar laws affecting the enforcement of creditors’ rights
generally and general equitable principles, regardless of whether
such enforceability is considered in a proceeding at law or in
equity (“ Bankruptcy Exceptions
”). The shares of Common Stock issuable upon
exercise of the Warrant (the “ Warrant Shares ”)
have been duly authorized and reserved for issuance upon exercise
of the Warrant and when so issued in accordance with the terms of
the Warrant will be validly issued, fully paid and non-assessable,
subject, if applicable, to the approvals of its stockholders set
forth on Schedule C .
(e)
Authorization, Enforceability .
(i) The
Company has the corporate power and authority to execute and
deliver this Agreement and the Warrant and, subject, if applicable,
to the approvals of its stockholders set forth on Schedule C
, to carry out its obligations hereunder and thereunder (which
includes the issuance of the Preferred Shares, Warrant and Warrant
Shares). The execution, delivery and performance by the
Company of this Agreement and the Warrant and the consummation of
the transactions contemplated hereby and thereby have been duly
authorized by all necessary corporate action on the part of the
Company and its stockholders, and no further approval or
authorization is required on the part of the Company, subject, in
each case, if applicable, to the approvals of its stockholders set
forth on Schedule C . This Agreement is a valid
and binding obligation of the Company enforceable against the
Company in accordance with its terms, subject to the Bankruptcy
Exceptions.
(ii) The
execution, delivery and performance by the Company of this
Agreement and the Warrant and the consummation of the transactions
contemplated hereby and thereby and compliance by the Company with
the provisions hereof and thereof, will not (A) violate, conflict
with, or result in a breach of any provision of, or constitute a
default (or an event which, with notice or lapse of time or both,
would constitute a default) under, or result in the termination of,
or accelerate the performance required by, or result in a right of
termination or acceleration of, or result in the creation of, any
lien, security interest, charge or encumbrance upon any of the
properties or assets of the Company or any Company Subsidiary under
any of the terms, conditions or provisions of (i) subject, if
applicable, to the approvals of the Company’s stockholders
set forth on Schedule C , its organizational documents or
(ii) any note, bond, mortgage, indenture, deed of trust, license,
lease, agreement or other instrument or obligation to which the
Company or any Company Subsidiary is a party or by which it or any
Company Subsidiary may be bound, or to which the Company or any
Company Subsidiary or any of the properties or assets of the
Company or any Company Subsidiary may be subject, or (B) subject to
compliance with the statutes and regulations referred to in the
next paragraph, violate any statute, rule or regulation or any
judgment, ruling, order, writ, injunction or decree applicable to
the Company or any Company Subsidiary or any of their respective
properties or assets except, in the case of clauses (A)(ii) and
(B), for those occurrences that, individually or in the aggregate,
have not had and would not reasonably be expected to have a Company
Material Adverse Effect.
(iii) Other
than the filing of the Certificate of Designations with the
Secretary of State of its jurisdiction of organization or other
applicable Governmental Entity, any current report on Form 8-K
required to be filed with the SEC, such filings and approvals as
are required to be made or obtained under any state “blue
sky” laws, the filing of any proxy statement contemplated by
Section 3.1 and such as have been made or obtained, no notice to,
filing with, exemption or review by, or authorization, consent or
approval of, any Governmental Entity is required to be made or
obtained by the Company in connection with the consummation by the
Company of the Purchase except for any such notices, filings,
exemptions, reviews, authorizations, consents and approvals the
failure of which to make or obtain would not, individually or in
the aggregate, reasonably be expected to have a Company Material
Adverse Effect.
(f)
Anti-takeover Provisions and Rights Plan . The
Board of Directors of the Company (the “ Board of
Directors ”) has taken all necessary action to ensure
that the transactions contemplated by this Agreement and the
Warrant and the consummation of the transactions contemplated
hereby and thereby, including the exercise of the Warrant in
accordance with its terms, will be exempt from any anti-takeover or
similar provisions of the Company’s Charter and bylaws, and
any other provisions of any applicable “moratorium”,
“control share”, “fair price”,
“interested stockholder” or other anti-takeover laws
and regulations of any jurisdiction. The Company has
taken all actions necessary to render any stockholders’
rights plan of the Company inapplicable to this Agreement and the
Warrant and the consummation of the transactions contemplated
hereby and thereby, including the exercise of the Warrant by the
Investor in accordance with its terms.
(g)
No Company Material Adverse Effect . Since the
last day of the last completed fiscal period for which the Company
has filed a Quarterly Report on Form 10-Q or an Annual Report on
Form 10-K with the SEC prior to the Signing Date, no fact,
circumstance, event, change, occurrence, condition or development
has occurred that, individually or in the aggregate, has had or
would reasonably be expected to have a Company Material Adverse
Effect.
(h)
Company Financial Statements . Each of the
consolidated financial statements of the Company and its
consolidated subsidiaries (collectively the “ Company
Financial Statements ”) included or incorporated by
reference in the Company Reports filed with the SEC since December
31, 2006, present fairly in all material respects the consolidated
financial position of the Company and its consolidated subsidiaries
as of the dates indicated therein (or if amended prior to the
Signing Date, as of the date of such amendment) and the
consolidated results of their operations for the periods specified
therein; and except as stated therein, such financial statements
(A) were prepared in conformity with GAAP applied on a consistent
basis (except as may be noted therein), (B) have been prepared
from, and are in accordance with, the books and records of the
Company and the Company Subsidiaries and (C) complied as to form,
as of their respective dates of filing with the SEC, in all
material respects with the applicable accounting requirements and
with the published rules and regulations of the SEC with respect
thereto.
(i)
Reports .
(i) Since
December 31, 2006, the Company and each subsidiary of the Company
(each a “ Company Subsidiary ” and,
collectively, the “ Company Subsidiaries ”) has
timely filed all reports, registrations, documents, filings,
statements and submissions, together with any amendments thereto,
that it was required to file with any Governmental Entity (the
foregoing, collectively, the “ Company Reports
”) and has paid all fees and assessments due and payable in
connection therewith, except, in each case, as would not,
individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect. As of their respective
dates of filing, the Company Reports complied in all material
respects with all statutes and applicable rules and regulations of
the applicable Governmental Entities. In the case of
each such Company Report filed with or furnished to the SEC, such
Company Report (A) did not, as of its date or if amended prior to
the Signing Date, as of the date of such amendment, contain an
untrue statement of a material fact or omit to state a material
fact necessary in order to make the statements made therein, in
light of the circumstances under which they were made, not
misleading, and (B) complied as to form in all material respects
with the applicable requirements of the Securities Act and the
Exchange Act. With respect to all other Company Reports,
the Company Reports were complete and accurate in all material
respects as of their respective dates. No executive
officer of the Company or any Company Subsidiary has failed in any
respect to make the certifications required of him or her under
Section 302 or 906 of the Sarbanes-Oxley Act of 2002.
(ii) The
records, systems, controls, data and information of the Company and
the Company Subsidiaries are recorded, stored, maintained and
operated under means (including any electronic, mechanical or
photographic process, whether computerized or not) that are under
the exclusive ownership and direct control of the Company or the
Company Subsidiaries or their accountants (including all means of
access thereto and therefrom), except for any non-exclusive
ownership and non-direct control that would not reasonably be
expected to have a material adverse effect on the system of
internal accounting controls described below in this Section
2.2(i)(ii). The Company (A) has implemented and
maintains disclosure controls and procedures (as defined in Rule
13a-15(e) of the Exchange Act) to ensure that material information
relating to the Company, including the consolidated Company
Subsidiaries, is made known to the chief executive officer and the
chief financial officer of the Company by others within those
entities, and (B) has disclosed, based on its most recent
evaluation prior to the Signing Date, to the Company’s
outside auditors and the audit committee of the Board of Directors
(x) any significant deficiencies and material weaknesses in the
design or operation of internal controls over financial reporting
(as defined in Rule 13a-15(f) of the Exchange Act) that are
reasonably likely to adversely affect the Company’s ability
to record, process, summarize and report financial information and
(y) any fraud, whether or not material, that involves management or
other employees who have a significant role in the Company’s
internal controls over financial reporting.
(j)
No Undisclosed Liabilities . Neither the Company
nor any of the Company Subsidiaries has any liabilities or
obligations of any nature (absolute, accrued, contingent or
otherwise) which are not properly reflected or reserved against in
the Company Financial Statements to the extent required to be so
reflected or reserved against in accordance with GAAP, except for
(A) liabilities that have arisen since the last fiscal year end in
the ordinary and usual course of business and consistent with past
practice and (B) liabilities that, individually or in the
aggregate, have not had and would not reasonably be expected to
have a Company Material Adverse Effect.
(k)
Offering of Securities . Neither the Company nor
any person acting on its behalf has taken any action (including any
offering of any securities of the Company under circumstances which
would require the integration of such offering with the offering of
any of the Purchased Securities under the Securities Act, and the
rules and regulations of the SEC promulgated thereunder), which
might subject the offering, issuance or sale of any of the
Purchased Securities to Investor pursuant to this Agreement to the
registration requirements of the Securities Act.
(l)
Litigation and Other Proceedings . Except (i) as
set forth on Schedule D or (ii) as would not, individually
or in the aggregate, reasonably be expected to have a Company
Material Adverse Effect, there is no (A) pending or, to the
knowledge of the Company, threatened, claim, action, suit,
investigation or proceeding, against the Company or any Company
Subsidiary or to which any of their assets are subject nor is the
Company or any Company Subsidiary subject to any order, judgment or
decree or (B) unresolved violation, criticism or exception by any
Governmental Entity with respect to any report or relating to any
examinations or inspections of the Company or any Company
Subsidiaries.
(m)
Compliance with Laws
. Except as would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect,
the Company and theCompany Subsidiaries have all permits, licenses,
franchises, authorizations, orders and approvals of, and have made
all filings, applications and registrations with, Governmental
Entities that are required in order to permit them to own or lease
their properties and assets and to carry on their business as
presently conducted and that are material to the business of the
Company or such Company Subsidiary. Except as set forth
on Schedule E , the Company and the Company Subsidiaries
have complied in all respects and are not in default or violation
of, and none of them is, to the knowledge of the Company, under
investigation with respect to or, to the knowledge of the Company,
have been threatened to be charged with or given notice of any
violation of, any applicable domestic (federal, state or local) or
foreign law, statute, ordinance, license, rule, regulation, policy
or guideline, order, demand, writ, injunction, decree or judgment
of any Governmental Entity, other than such noncompliance, defaults
or violations that would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse
Effect. Except for statutory or regulatory restrictions
of general application or as set forth on Schedule E , no
Governmental Entity has placed any restriction on the business or
properties of the Company or any Company Subsidiary that would,
individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect.
(n) Employee
Benefit Matters. Except as would not reasonably be
expected to have, either individually or in the aggregate, a
Company Material Adverse Effect: (A) each “employee benefit
plan” (within the meaning of Section 3(3) of the Employee
Retirement Income Security Act of 1974, as amended (“
ERISA ”)) providing benefits to any current or former
employee, officer or director of the Company or any member of its
“ Controlled Group ” (defined as any
organization which is a member of a controlled group of
corporations within the meaning of Section 414 of the Internal
Revenue Code of 1986, as amended (the “ Code ”))
that is sponsored, maintained or contributed to by the Company or
any member of its Controlled Group and for which the Company or any
member of its Controlled Group would have any liability, whether
actual or contingent (each, a “ Plan ”) has been
maintained in compliance with its terms and with the requirements
of all applicable statutes, rules and regulations, including ERISA
and the Code; (B) with respect to each Plan subject to Title IV of
ERISA (including, for purposes of this clause (B), any plan subject
to Title IV of ERISA that the Company or any member of its
Controlled Group previously maintained or contributed to in the six
years prior to the Signing Date), (1) no “reportable
event” (within the meaning of Section 4043(c) of ERISA),
other than a reportable event for which the notice period referred
to in Section 4043(c) of ERISA has been waived, has occurred in the
three years prior to the Signing Date or is reasonably expected to
occur, (2) no “accumulated funding deficiency” (within
the meaning of Section 302 of ERISA or Section 412 of the Code),
whether or not waived, has occurred in the three years prior to the
Signing Date or is reasonably expected to occur, (3) the fair
market value of the assets under each Plan exceeds the present
value of all benefits accrued under such Plan (determined based on
the assumptions used to fund such Plan) and (4) neither the Company
nor any member of its Controlled Group has incurred in the six
years prior to the Signing Date, or reasonably expects to incur,
any liability under Title IV of ERISA (other than contributions to
the Plan or premiums to the PBGC in the ordinary course and without
default) in respect of a Plan (including any Plan that is a
“multiemployer plan”, within the meaning of Section
4001(c)(3) of ERISA); and (C) each Plan that is intended to be
qualified under Section 401(a) of the Code has received a
favorable
determination
letter from the Internal Revenue Service with respect to its
qualified status that has not been revoked, or such a determination
letter has been timely applied for but not received by the Signing
Date, and nothing has occurred, whether by action or by failure to
act, which could reasonably be expected to cause the loss,
revocation or denial of such qualified status or favorable
determination letter.
(o) Taxes. Except
as would not, individually or in the aggregate, reasonably be
expected to have a Company Material Adverse Effect, (i) the Company
and the Company Subsidiaries have filed all federal, state, local
and foreign income and franchise Tax returns required to be filed
through the Signing Date, subject to permitted extensions, and have
paid all Taxes due thereon, and (ii) no Tax deficiency has been
determined adversely to the Company or any of the Company
Subsidiaries, nor does the Company have any knowledge of any Tax
deficiencies. “ Tax ” or “
Taxes ” means any federal, state, local or foreign
income, gross receipts, property, sales, use, license, excise,
franchise, employment, payroll, withholding, alternative or add on
minimum, ad valorem, transfer or excise tax, or any other tax,
custom, duty, governmental fee or other like assessment or charge
of any kind whatsoever, together with any interest or penalty,
imposed by any Governmental Entity.
(p)
Properties and Leases . Except as would not,
individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect, the Company and the Company
Subsidiaries have good and marketable title to all real properties
and all other properties and assets owned by them, in each case
free from liens, encumbrances, claims and defects that would affect
the value thereof or interfere with the use made or to be made
thereof by them. Except as would not, individually or in
the aggregate, reasonably be expected to have a Company Material
Adverse Effect, the Company and the Company Subsidiaries hold all
leased real or personal property under valid and enforceable leases
with no exceptions that would interfere with the use made or to be
made thereof by them.
(q)
Environmental Liability . Except as would not,
individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect:
(i) there
is no legal, administrative, or other proceeding, claim or action
of any nature seeking to impose, or that would reasonably be
expected to result in the imposition of, on the Company or any
Company Subsidiary, any liability relating to the release of
hazardous substances as defined under any local, state or federal
environmental statute, regulation or ordinance, including the
Comprehensive Environmental Response, Compensation and Liability
Act of 1980, pending or, to the Company’s knowledge,
threatened against the Company or any Company
Subsidiary;
(ii) to
the Company’s knowledge, there is no reasonable basis for any
such proceeding, claim or action; and
(iii) neither
the Company nor any Company Subsidiary is subject to any agreement,
order, judgment or decree by or with any court, Governmental Entity
or third party imposing any such environmental
liability.
(r)
Risk Management Instruments . Except as would
not, individually or in the aggregate, reasonably be expected to
have a Company Material Adverse Effect, all derivative instruments,
including, swaps, caps, floors and option agreements, whether
entered into for the Company’s own account, or for the
account of one or more of the Company Subsidiaries or its or their
customers, were entered into (i) only in the ordinary course of
business, (ii) in accordance with prudent practices and in all
material respects with all applicable laws, rules, regulations and
regulatory policies and (iii) with counterparties believed to be
financially responsible at the time; and each of such instruments
constitutes the valid and legally binding obligation of the Company
or one of the Company Subsidiaries, enforceable in accordance with
its terms, except as may be limited by the Bankruptcy
Exceptions. Neither the Company or the Company
Subsidiaries, nor, to the knowledge of the Company, any other party
thereto, is in breach of any of its obligations under any such
agreement or arrangement other than such breaches that would not,
individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect.
(s)
Agreements with Regulatory Agencies . Except as
set forth on Schedule F , neither the Company nor any
Company Subsidiary is subject to any material cease-and-desist or
other similar order or enforcement action issued by, or is a party
to any material written agreement, consent agreement or memorandum
of understanding with, or is a party to any commitment letter or
similar undertaking to, or is subject to any capital directive by,
or since December 31, 2006, has adopted any board resolutions at
the request of, any Governmental Entity (other than the Appropriate
Federal Banking Agencies with jurisdiction over the Company and the
Company Subsidiaries) that currently restricts in any material
respect the conduct of its business or that in any material manner
relates to its capital adequacy, its liquidity and funding policies
and practices, its ability to pay dividends, its credit, risk
management or compliance policies or procedures, its internal
controls, its management or its operations or business (each item
in this sentence, a “ Regulatory Agreement ”),
nor has the Company or any Company Subsidiary been advised since
December 31, 2006 by any such Governmental Entity that it is
considering issuing, initiating, ordering, or requesting any such
Regulatory Agreement. The Company and each Company
Subsidiary are in compliance in all material respects with each
Regulatory Agreement to which it is party or subject, and neither
the Company nor any Company Subsidiary has received any notice from
any Governmental Entity indicating that either the Company or any
Company Subsidiary is not in compliance in all material respects
with any such Regulatory Agreement. “
Appropriate Federal Banking Agency ” means the
“appropriate Federal banking agency” with respect to
the Company or such Company Subsidiaries, as applicable, as defined
in Section 3(q) of the Federal Deposit Insurance Act (12 U.S.C.
Section 1813(q)).
(t)
Insurance . The Company and the Company
Subsidiaries are insured with reputable insurers against such risks
and in such amounts as the management of the Company reasonably has
determined to be prudent and consistent with industry
practice. The Company and the Company Subsidiaries are
in material compliance with their insurance policies and are not in
default under any of the material terms thereof, each such policy
is outstanding and in full force and effect, all premiums and other
payments due under any material policy have been paid, and all
claims thereunder have been filed in due and timely fashion,
except, in each case, as would not, individually or in the
aggregate, reasonably be expected to have a Company Material
Adverse Effect.
(u)
Intellectual Property . Except as would not,
individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect, (i) the Company and each Company
Subsidiary owns or otherwise has the right to use, all intellectual
property rights, including all trademarks, trade dress, trade
names, service marks, domain names, patents, inventions, trade
secrets, know-how, works of authorship and copyrights therein, that
are used in the conduct of their existing businesses and all rights
relating to the plans, design and specifications of any of its
branch facilities (“ Proprietary Rights ”) free
and clear of all liens and any claims of ownership by current or
former employees, contractors, designers or others and (ii) neither
the Company nor any of the Company Subsidiaries is materially
infringing, diluting, misappropriating or violating, nor has the
Company or any or the Company Subsidiaries received any written
(or, to the knowledge of the Company, oral) communications alleging
that any of them has materially infringed, diluted, misappropriated
or violated, any of the Proprietary Rights owned by any other
person. Except as would not, individually or in the
aggregate, reasonably be expected to have a Company Material
Adverse Effect, to the Company’s knowledge, no other person
is infringing, diluting, misappropriating or violating, nor has the
Company or any or the Company Subsidiaries sent any written
communications since January 1, 2006 alleging that any person has
infringed, diluted, misappropriated or violated, any of the
Proprietary Rights owned by the Company and the Company
Subsidiaries.
(v)
Brokers and Finders . No broker, finder or
investment banker is entitled to any financial advisory, brokerage,
finder’s or other fee or commission in connection with this
Agreement or the Warrant or the transactions contemplated hereby or
thereby based upon arrangements made by or on behalf of the Company
or any Company Subsidiary for which the Investor could have any
liability.
Article III
Covenants
3.1
Commercially Reasonable Efforts .
(a) Subject
to the terms and conditions of this Agreement, each of the parties
will use its commercially reasonable efforts in good faith to take,
or cause to be taken, all actions, and to do, or cause to be done,
all things necessary, proper or desirable, or advisable under
applicable laws, so as to permit consummation of the Purchase as
promptly as practicable and otherwise to enable consummation of the
transactions contemplated hereby and shall use commercially
reasonable efforts to cooperate with the other party to that
end.
(b) If
the Company is required to obtain any stockholder approvals set
forth on Schedule C , then the Company shall comply with
this Section 3.1(b) and Section 3.1(c). The Company
shall call a special meeting of its stockholders, as promptly as
practicable following the Closing, to vote on proposals
(collectively, the “ Stockholder Proposals ”) to
(i) approve the exercise of the Warrant for Common Stock for
purposes of the rules of the national security exchange on which
the Common Stock is listed and/or (ii) amend the Company’s
Charter to increase the number of authorized shares of Common Stock
to at least such number as shall be sufficient to permit the full
exercise of the Warrant for Common Stock and comply with theother
provisions of this Section 3.1(b) and Section
3.1(c). The Board of Directors shall recommend to the
Company’s stockholders that such stockholders
vote in favor
of the Stockholder Proposals. In connection with such
meeting, the Company shall prepare (and the Investor will
reasonably cooperate with the Company to prepare) and file with the
SEC as promptly as practicable (but in no event more than ten
business days after the Closing) a preliminary proxy statement,
shall use its reasonable best efforts to respond to any comments of
the SEC or its staff thereon and to cause a definitive proxy
statement related to such stockholders’ meeting to be mailed
to the Company’s stockholders not more than five business
days after clearance thereof by the SEC, and shall use its
reasonable best efforts to solicit proxies for such stockholder
approval of the Stockholder Proposals. The Company shall
notify the Investor promptly of the receipt of any comments from
the SEC or its staff with respect to the proxy statement and of any
request by the SEC or its staff for amendments or supplements to
such proxy statement or for additional information and will supply
the Investor with copies of all correspondence between the Company
or any of its representatives, on the one hand, and the SEC or its
staff, on the other hand, with respect to such proxy
statement. If at any time prior to such
stockholders’ meeting there shall occur any event that is
required to be set forth in an amendment or supplement to the proxy
statement, the Company shall as promptly as practicable prepare and
mail to its stockholders such an amendment or
supplement. Each of the Investor and the Company agrees
promptly to correct any information provided by it or on its behalf
for use in the proxy statement if and to the extent that such
information shall have become false or misleading in any material
respect, and the Company shall as promptly as practicable prepare
and mail to its stockholders an amendment or supplement to correct
such information to the extent required by applicable laws and
regulations. The Company shall consult with the Investor
prior to filing any proxy statement, or any amendment or supplement
thereto, and provide the Investor with a reasonable opportunity to
comment thereon. In the event that the approval of any
of the Stockholder Proposals is not obtained at such special
stockholders meeting, the Company shall include a proposal to
approve (and the Board of Directors shall recommend approval of)
each such proposal at a meeting of its stockholders no less than
once in each subsequent six- month period beginning on January 1,
2009 until all such approvals are obtained or made.
(c) None
of the information supplied by the Company or any of the Company
Subsidiaries for inclusion in any proxy statement in connection
with any such stockholders meeting of the Company will, at the date
it is filed with the SEC, when first mailed to the Company’s
stockholders and at the time of any stockholders meeting, and at
the time of any amendment or supplement thereof, contain any untrue
statement of a material fact or omit to state any material fact
necessary in order to make the statements therein, in light of the
circumstances under which they are made, not misleading.
3.2
Expenses . Unless otherwise provided in this
Agreement or the Warrant, each of the parties hereto will
bear and pay all costs and expenses incurred by it or on
its behalf in connection with the transactions contemplated under
this Agreement and the Warrant, including fees and expenses of its
own financial or other consultants, investment bankers, accountants
and counsel.
3.3
Sufficiency of Authorized Common Stock; Exchange Listing
.
(a) During
the period from the Closing Date (or, if the approval of the
Stockholder Proposals is required, the date of such approval) until
the date on which the Warrant has been fully exercised, the Company
shall at all times have reserved for issuance, free of preemptive
or similar rights, a sufficient number of authorized and unissued
Warrant Shares to effectuate such exercise. Nothing in
this Section 3.3 shall preclude the Company from satisfying its
obligations in respect of the exercise of the Warrant by delivery
of shares of Common Stock which are held in the treasury of the
Company. As soon as reasonably practicable following the
Closing, the Company shall, at its expense, cause the Warrant
Shares to be listed on the same national securities exchange on
which the Common Stock is listed, subject to official notice of
issuance, and shall maintain such listing for so long as any Common
Stock is listed on such exchange.
(b) If
requested by the Investor, the Company shall promptly use its
reasonable best efforts to cause the Preferred Shares to be
approved for listing on a national securities exchange as promptly
as practicable following such request.
3.4
Certain Notifications Until Closing . From the
Signing Date until the Closing, the Company shall promptly notify
the Investor of (i) any fact, event or circumstance of which it is
aware and which would reasonably be expected to cause any
representation or warranty of the Company contained in this
Agreement to be untrue or inaccurate in any material respect or to
cause any covenant or agreement of the Company contained in this
Agreement not to be complied with or satisfied in any material
respect and (ii) except as Previously Disclosed, any fact,
circumstance, event, change, occurrence, condition or development
of which the Company is aware and which, individually or in the
aggregate, has had or would reasonably be expected to have a
Company Material Adverse Effect; provided, however , that
delivery of any notice pursuant to this Section 3.4 shall not limit
or affect any rights of or remedies available to the Investor;
provided, further , that a failure to comply with this
Section 3.4 shall not constitute a breach of this Agreement or the
failure of any condition set forth in Section 1.2 to be satisfied
unless the underlying Company Material Adverse Effect or material
breach would independently result in the failure of a condition set
forth in Section 1.2 to be satisfied.
3.5
Access, Information and Confidentiality .
(a) From
the Signing Date until the date when the Investor holds an amount
of Preferred Shares having an aggregate liquidation value of less
than 10% of the Purchase Price, the Company will permit the
Investor and its agents, consultants, contractors and advisors (x)
acting through the Appropriate Federal Banking Agency, to examine
the corporate books and make copies thereof and to discuss the
affairs, finances and accounts of the Company and the Company
Subsidiaries with the principal officers of the Company, all upon
reasonable notice and at such reasonable times and as often as the
Investor may reasonably request and (y) to review any information
material to the Investor’s investment in the Company provided
by the Company to its Appropriate Federal Banking
Agency. Any investigation pursuant to this Section 3.5
shall be conducted during normal business hours and in such manner
as not to interfere unreasonably with the conduct of the business
of the Company, and nothing herein shall require the Company or any
Company Subsidiary to disclose any information to the Investor to
the extent (i) prohibited by applicable law or regulation, or (ii)
that such disclosure would reasonably be expected to cause a
violation of any agreement to which the Company or any Company
Subsidiary is a party or would cause a risk of a loss of privilege
to the Company or any Company Subsidiary ( provided that the
Company shall use commercially reasonable efforts to make
appropriate substitute disclosure arrangements under circumstances
where the restrictions in this clause (ii) apply).
(b) The
Investor will use reasonable best efforts to hold, and will use
reasonable best efforts to cause its agents, consultants,
contractors and advisors to hold, in confidence all nonpublic
records, books, contracts, instruments, computer data and other
data and information (collectively, “ Information
”) concerning the Company furnished or made available to it
by the Company or its representatives pursuant to this Agreement
(except to the extent that such information can be shown to have
been (i) previously known by such party on a non-confidential
basis, (ii) in the public domain through no fault of such party or
(iii) later lawfully acquired from other sources by the party to
which it was furnished (and without violation of any other
confidentiality obligation)); provided that nothing herein
shall prevent the Investor from disclosing any Information to the
extent required by applicable laws or regulations or by any
subpoena or similar legal process.
Article IV
Additional
Agreements
4.1
Purchase for Investment . The Investor
acknowledges that the Purchased Securities and the Warrant Shares
have not been registered under the Securities Act or under any
state securities laws. The Investor (a) is acquiring the
Purchased Securities pursuant to an exemption from registration
under the Securities Act solely for investment with no present
intention to distribute them to any person in violation of the
Securities Act or any applicable U.S. state securities laws, (b)
will not sell or otherwise dispose of any of the Purchased
Securities or the Warrant Shares, except in compliance with the
registration requirements or exemption provisions of the Securities
Act and any applicable U.S. state securities laws, and (c) has such
knowledge and experience in financial and business matters and in
investments of this type that it is capable of evaluating the
merits and risks of the Purchase and of making an informed
investment decision.
4.2
Legends .
(a) The
Investor agrees that all certificates or other instruments
representing the Warrant and the Warrant Shares will bear a legend
substantially to the following effect:
“THE
SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES
LAWS OF ANY STATE AND MAY NOT BE TRANSFERRED, SOLD OR OTHERWISE
DISPOSED OF EXCEPT WHILE A REGISTRATION STATEMENT RELATING THERETO
IS IN EFFECT UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR
PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT OR SUCH
LAWS.”
(b) The
Investor agrees that all certificates or other instruments
representing the Warrant will also bear a legend substantially to
the following effect:
“THIS
INSTRUMENT IS ISSUED SUBJECT TO THE RESTRICTIONS ON TRANSFER AND
OTHER PROVISIONS OF A SECURITIES PURCHASE AGREEMENT BETWEEN THE
ISSUER OF THESE SECURITIES AND THE INVESTOR REFERRED TO THEREIN, A
COPY OF WHICH IS ON FILE WITH THE ISSUER. THE SECURITIES
REPRESENTED BY THIS INSTRUMENT MAY NOT BE SOLD OR OTHERWISE
TRANSFERRED EXCEPT IN COMPLIANCE WITH SAID
AGREEMENT. ANY SALE OR OTHER TRANSFER NOT IN COMPLIANCE
WITH SAID AGREEMENT WILL BE VOID.”
(c) In
addition, the Investor agrees that all certificates or other
instruments representing the Preferred Shares will bear a legend
substantially to the following effect:
“THE
SECURITIES REPRESENTED BY THIS INSTRUMENT ARE NOT SAVINGS ACCOUNTS,
DEPOSITS OR OTHER OBLIGATIONS OF A BANK AND ARE NOT INSURED BY THE
FEDERAL DEPOSIT INSURANCE CORPORATION OR ANY OTHER GOVERNMENTAL
AGENCY.
THE SECURITIES
REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE
TRANSFERRED, SOLD OR OTHERWISE DISPOSED OF EXCEPT WHILE A
REGISTRATION STATEMENT RELATING THERETO IS IN EFFECT UNDER SUCH ACT
AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN EXEMPTION
FROM REGISTRATION UNDER SUCH ACT OR SUCH LAWS. EACH
PURCHASER OF THE SECURITIES REPRESENTED BY THIS INSTRUMENT IS
NOTIFIED THAT THE SELLER MAY BE RELYING ON THE EXEMPTION FROM
SECTION 5 OF THE SECURITIES ACT PROVIDED BY RULE 144A
THEREUNDER. ANY TRANSFEREE OF THE SECURITIES REPRESENTED
BY THIS INSTRUMENT BY ITS ACCEPTANCE HEREOF (1) REPRESENTS THAT IT
IS A “QUALIFIED INSTITUTIONAL BUYER” (AS DEFINED IN
RULE 144A UNDER THE SECURITIES ACT), (2) AGREES THAT IT WILL NOT
OFFER, SELL OR OTHERWISE TRANSFER THE SECURITIES REPRESENTED BY
THIS INSTRUMENT EXCEPT (A) PURSUANT TO A REGISTRATION STATEMENT
WHICH IS THEN EFFECTIVE UNDER THE SECURITIES ACT, (B) FOR SO LONG
AS THE SECURITIES REPRESENTED BY THIS INSTRUMENT ARE ELIGIBLE FOR
RESALE PURSUANT TO RULE 144A, TO A PERSON IT REASONABLY BELIEVES IS
A “QUALIFIED INSTITUTIONAL BUYER” AS DEFINED IN RULE
144A UNDER THE SECURITIES ACT THAT PURCHASES FOR ITS OWN ACCOUNT OR
FOR THE ACCOUNT OF A QUALIFIED INSTITUTIONAL BUYER TO WHOM NOTICE
IS GIVEN THAT THE TRANSFER IS BEING MADE IN RELIANCE ON RULE 144A,
(C) TO THE ISSUER OR (D) PURSUANT TO ANY OTHER AVAILABLE EXEMPTION
FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND (3)
AGREES THAT IT WILL GIVE TO EACH PERSON TO WHOM THE SECURITIES
REPRESENTED BY THIS INSTRUMENT ARE TRANSFERRED A NOTICE
SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND.”
(d) In
the event that any Purchased Securities or Warrant Shares (i)
become registered under the Securities Act or (ii) are eligible to
be transferred without restriction in accordance with Rule 144 or
another exemption from registration under the Securities Act (other
than Rule 144A), the Company shall issue new certificates or other
instruments representing such Purchased Securities or Warrant
Shares, which shall not contain the applicable legends in Sections
4.2(a) and (c) above; provided that the Investor surrenders
to the Company the previously issued certificates or other
instruments. Upon Transfer of all or a portion of the
Warrant in compliance with Section 4.4, the Company shall issue new
certificates or other instruments representing the Warrant, which
shall not contain the applicable legend in Section 4.2(b) above;
provided that the Investor surrenders to the Company the
previously issued certificates or other instruments.
4.3
Certain Transactions . The Company will not merge
or consolidate with, or sell, transfer or lease all or
substantially all of its property or assets to, any other party
unless the successor, transferee or lessee party (or its ultimate
parent entity), as the case may be (if not the Company), expressly
assumes the due and punctual performance and observance of each and
every covenant, agreement and condition of this Agreement to be
performed and observed by the Company.
4.4
Transfer of Purchased Securities and Warrant Shares;
Restrictions on Exercise of the Warrant . Subject to
compliance with applicable securities laws, the Investor shall be
permitted to transfer, sell, assign or otherwise dispose of
(“ Transfer ”) all or a portion of the Purchased
Securities or Warrant Shares at any time, and the Company shall
take all steps as may be reasonably requested by the Investor to
facilitate the Transfer of the Purchased Securities and the Warrant
Shares; provided that the Investor shall not Transfer a
portion or portions of the Warrant with respect to, and/or exercise
the Warrant for, more than one-half of the Initial Warrant Shares
(as such number may be adjusted from time to time pursuant to
Section 13 thereof) in the aggregate until the earlier of (a) the
date on which the Company (or any successor by Business
Combination) has received aggregate gross proceeds of not less than
the Purchase Price (and the purchase price paid by the Investor to
any such successor for securities of such successor purchased under
the CPP) from one or more Qualified Equity Offerings (including
Qualified Equity Offerings of such successor) and (b) December 31,
2009. “ Qualified Equity Offering ”
means the sale and issuance for cash by the Company to persons
other than the Company or any of the Company Subsidiaries after the
Closing Date of shares of perpetual Preferred Stock, Common Stock
or any combination of such stock, that, in each case, qualify as
and may be included in Tier 1 capital of the Company at the time of
issuance under the applicable risk-based capital guidelines of the
Company’s Appropriate Federal Banking Agency (other than any
such sales and issuances made pursuant to agreements or
arrangements entered into, or pursuant to financing plans which
were publicly announced, on or prior to October 13,
2008). “Business Combination” means
a merger, consolidation, statutory share exchange or similar
transaction that requires the approval of the Company’s
stockholders.
4.5
Registration Rights .
(i) Subject
to the terms and conditions of this Agreement, the Company
covenants and agrees that as promptly as practicable after the
Closing Date (and in any event no later than 30 days after the
Closing Date), the Company shall prepare and file with the SEC a
Shelf Registration Statement covering all Registrable Securities
(or otherwise designate an existing Shelf Registration Statement
filed with the SEC to cover the Registrable Securities), and, to
the extent the Shelf Registration Statement has not theretofore
been declared effective or is not automatically effective upon such
filing, the Company shall use reasonable best efforts to cause such
Shelf Registration Statement to be declared or become effective and
to keep such Shelf Registration Statement continuously effective
and in compliance with the Securities Act and usable for resale of
such Registrable Securities for a period from the date of its
initial effectiveness until such time as there are no Registrable
Securities remaining (including by refiling such Shelf Registration
Statement (or a new Shelf Registration Statement) if the initial
Shelf Registration Statement expires). So long as the
Company is a well-known seasoned issuer (as defined in Rule 405
under the Securities Act) at the time of filing of the Shelf
Registration Statement with the SEC, such Shelf Registration
Statement shall be designated by the Company as an automatic Shelf
Registration Statement. Notwithstanding the foregoing,
if on the Signing Date the Company is not eligible to file a
registration statement on Form S-3, then the Company shall not be
obligated to file a Shelf Registration Statement unless and until
requested to do so in writing by the Investor.
(ii) Any
registration pursuant to Section 4.5(a)(i) shall be effected by
means of a shelf registration on an appropriate form under Rule 415
under the Securities Act (a “Shelf Registration
Statement” ). If the Investor or any other
Holder intends to distribute any Registrable Securities by means of
an underwritten offering it shall promptly so advise the Company
and the Company shall take all reasonable steps to facilitate such
distribution, including the actions required pursuant to Section
4.5(c); provided that the Company shall not be required to
facilitate an underwritten offering of Registrable Securities
unless the expected gross proceeds from such offering exceed (i) 2%
of the initial aggregate liquidation preference of the Preferred
Shares if such initial aggregate liquidation preference is less
than $2 billion and (ii) $200 million if the initial aggregate
liquidation preference of the Preferred Shares is equal to or
greater than $2 billion. The lead underwriters in any
such distribution shall be selected by the Holders of a majority of
the Registrable Securities to be distributed; provided that
to the extent appropriate and permitted under applicable law, such
Holders shall consider the qualifications of any broker-dealer
Affiliate of the Company in selecting the lead underwriters in any
such distribution.
(iii) The
Company shall not be required to effect a registration (including a
resale of Registrable Securities from an effective Shelf
Registration Statement) or an underwritten offering pursuant to
Section 4.5(a): (A) with respect to securities that are not
Registrable Securities; or (B) if the Company has notified the
Investor and all other Holders that in the good faith judgment of
the Board of Directors, it would be materially detrimental to the
Company or its securityholders for such registration or
underwritten offering to be effected at such time, in which event
the Company shall have the right to defer such registration for a
period of not more than 45 days after receipt of the request of the
Investor or any other Holder; provided that such right to
delay a registration or underwritten offering shall be exercised by
the Company (1) only if the Company has generally exercised (or is
concurrently exercising) similar black-out rights against holders
of similar securities that have registration rights and (2) not
more than three times in any 12-month period and not more than 90
days in the aggregate in any 12-month period.
(iv) If
during any period when an effective Shelf Registration Statement is
not available, the Company proposes to register any of its equity
securities, other than a registration pursuant to Section 4.5(a)(i)
or a Special Registration, and the registration form to be filed
may be used for the registration or qualification for distribution
of Registrable Securities, the Company will give prompt written
notice to the Investor and all other Holders of its intention to
effect such a registration (but in no event less than ten days
prior to the anticipated filing date) and will include in such
registration all Registrable Securities with respect to which the
Company has received written requests for inclusion therein within
ten business days after the date of the Company’s notice (a
“Piggyback Registration” ). Any such
person that has made such a written request may withdraw its
Registrable Securities from such Piggyback Registration by giving
written notice to the Company and the managing underwriter, if any,
on or before the fifth business day prior to the planned effective
date of such Piggyback Registration. The Company may
terminate or withdraw any registration under this Section
4.5(a)(iv) prior to the effectiveness of such registration, whether
or not Investor or any other Holders have elected to include
Registrable Securities in such registration.
(v) If
the registration referred to in Section 4.5(a)(iv) is proposed to
be underwritten, the Company will so advise Investor and all other
Holders as a part of the written notice given pursuant to Section
4. 5(a)(iv). In such event, the right of
Investor and all other Holders to registration pursuant to Section
4.5(a) will be conditioned upon such persons’ participation
in such underwriting and the inclusion of such person’s
Registrable Securities in the underwriting if such securities are
of the same class of securities as the securities to be offered in
the underwritten offering, and each such person will (together with
the Company and the other persons distributing their securities
through such underwriting) enter into an underwriting agreement in
customary form with the underwriter or underwriters selected for
such underwriting by the Company; provided that the Investor
(as opposed to other Holders) shall not be required to indemnify
any person in connection with any registration. If any
participating person disapproves of the terms of the underwriting,
such person may elect to withdraw therefrom by written notice to
the Company, the managing underwriters and the Investor (if the
Investor is participating in the underwriting).
(vi) If
either (x) the Company grants “piggyback” registration
rights to one or more third parties to include their
secu